Jeffrey Hagedorn, MD
Neurology · Columbus, INNPI 1679529879
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,127 and has fallen 93.1% since, to $146 in 2022.
Across 251 payments — averaging $11.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$631
- Supernus Pharmaceuticals, Inc.$328
- EMD Serono, Inc.$208
- Eisai Inc.$178
- Novartis$175
- Sanofi$170
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,893100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 65 | $631 |
| Supernus Pharmaceuticals, Inc. | 32 | $328 |
| EMD Serono, Inc. | 24 | $208 |
| Eisai Inc. | 10 | $178 |
| Novartis | 15 | $175 |
| Sanofi | 11 | $170 |
| Biogen | 9 | $141 |
| Teva Pharmaceuticals USA, Inc. | 12 | $115 |
| Genentech USA, Inc. | 9 | $110 |
| Sunovion Pharmaceuticals Inc. | 17 | $109 |
| Acadia Pharmaceuticals Inc | 6 | $92 |
| AbbVie | 4 | $78 |
| Greenwich Biosciences, Inc. | 3 | $61 |
| Jazz Pharmaceuticals Inc. | 4 | $53 |
| Lilly USA, LLC | 4 | $49 |
| AstraZeneca | 3 | $48 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Neurocrine Biosciences, Inc. | 3 | $40 |
| Adamas Pharmaceuticals, Inc. | 2 | $26 |
| Banner Life Sciences, LLC | 2 | $25 |
| Johnson & Johnson | 2 | $25 |
| Upsher-smith Laboratories LLC | 1 | $25 |
| Pfizer | 2 | $24 |
| Harmony Biosciences LLC | 1 | $21 |
| Amgen | 1 | $20 |
| GE HealthCare | 1 | $19 |
| MDD US Operations, LLC | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Aprecia Pharmaceuticals, LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| SK Life Science, Inc. | 1 | $15 |
How this compares
$2,893 in reported general payments places this provider in the 55th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ropinirole Hcl | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbus
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
- Andrea HallerFort Wayne$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.